Next steps for prostate cancer treatment

The next round of key opinion leader (KOL) research into the future of prostate cancer treatment has begun. Through discussions with 12 of the world’s leading oncologists on the unmet needs in existing treatments and the impact pipeline programmes can bring, this research aims to uncover insights on how the treatment landscape will evolve over the next three-to-five years. The research will follow the key lines of inquiry set out below.

Prostate cancer key intelligence areas—lines of inquiry

What are the key unmet needs that exist in the treatment of prostate cancer?

How do KOLs view the current treatment options of chemotherapy and anti-androgen inhibition?

Which next-generation androgen receptor Inhibitors do KOLs prefer, and why? How will their use and prescribing evolve in the near future?

In the US, how do KOLs perceive the recently approved agent Erleada (apalutamide; Johnson & Johnson) as a treatment for patients with non-metastatic castrate-resistant prostate cancer (CRPC)?

Which strategies do KOLs believe hold the most promise in prostate cancer; PARP inhibitors (e.g. Olaparib, rucaparib and talazoparib), anti-PD-1/PD-L1 checkpoint inhibitors (e.g. Keytruda, Tecentriq), other targeted agents (e.g. ipatasertib) and next-generation androgen inhibitors (e.g. darolutamide)?

What do KOLs think about other immunotherapy approaches including autologous dendritic cell (DC) therapies (e.g. DCVAC/PCA [stapuldencel-T; Sotio]) and viral-based therapies (e.g. ProstAtak [aglatimagene besadenovec; Advantagene])?

What expectations do KOLs have for key clinical trials including ENZAMET, ARCHES, SPARTAN, TITAN, ERA 223, PEACE III, IMbassador250, TOPARP, PROfound, TRITON3 and IPATential150, amongst many others?

Will personalised drug approaches shape the prostate cancer treatment paradigm and which players will pioneer this approach?

How is the treatment paradigm likely to evolve over the next three-to-five years, and what potential challenges and opportunities exist?